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ABSTRACT
Objective To understand the most significant aspects 
of care experienced by people in opioid substitution 
treatment (OST) in primary care settings.
Design Semistructured individual interviews were 
conducted, following the critical incidents technique. 
Interview transcripts were analysed following a thematic 
analysis approach.
Participants Adults aged 18 years or older, receiving OST 
in UK- based primary care services.
Results Twenty- four people in OST were interviewed 
between January and March 2019. Participants reported 
several aspects which were significant for their treatment, 
when engaging with the primary care service. These 
were grouped into 10 major themes: (1) humanised care; 
(2) individual bond/connection with the professional; (3) 
professionals’ experience and knowledge; (4) having 
holistic care; (5) familiarity; (6) professionals’ commitment 
and availability to help; (7) anonymity; (8) location; (9) 
collaborative teamwork; and (10) flexibility and changes 
around the treatment plan.
Conclusions This study included first- hand accounts of 
people who use drugs about what supports them in their 
recovery journey. The key lessons learnt from our findings 
indicate that people who use drugs value receiving 
treatment in humanised and destigmatised environments. 
We also learnt that a good relationship with primary 
care professionals supports their recovery journey, and 
that treatment plans should be flexible, tailor- made and 
collaboratively designed with patients.
INTRODUCTION
The prevalence of illicit drug use in the UK 
has remained stable over the last decade, with 
1 in 10 adults aged 16–59 years self- reporting 
using illicit drugs in the last year.1 However, 
drug mortality rates have been escalating, 
with the number of opioid- related deaths per 
year rising from 579 in 2012 to 1336 in 2018, 
the highest number and the highest annual 
increase (16%) since 1993.2
In the UK, treatment for drug use can be 
provided free of cost via the National Health 
Service (NHS). They recommend that general 
practitioners (GPs) are ‘a good place to start’ 
as they can ‘offer treatment at the practice’ 
or refer to a ‘local drug service’ for specialist 
treatment.3 Despite free and effective treat-
ment available, access to drug addiction treat-
ment is suboptimal in the UK.4 Moreover, 
reports have shown that only 48% of people 
successfully complete their treatment plans, 
and that the lowest rate of successful treat-
ment completion (25%) was found in people 
who use opioids.4
While many factors contribute to poor 
treatment outcomes, including comorbidity 
and inadequate dosing of opioid substitu-
tion treatment (OST) medication, it is likely 
that treatment delivery issues also play an 
important role. For example, in one study of 
OST in Australia, although overall satisfac-
tion with OST was quite high (3.8/5), issues 
related to clinic atmosphere, frequency of 
clinic attendance, dispensing hours and lack 
of takeaway doses were commonly cited as 
areas of concern for people.5 In other studies, 
issues located within the clinical population 
itself such as low motivation and conflicts 
with staff were among the most common 
Strengths and limitations of this study
 ► Good breadth of experiences coming from a di-
verse sample (different genders, various treatment 
lengths, four services across three UK cities).
 ► Balanced overview of aspects that make treatment 
helpful and hindering for people who use drugs.
 ► Limited representativeness to other people and set-
tings due to the study’s small sample size.
 ► Participants identified and selected by general prac-
titioners, which may have biased the recruitment 
process.
 ► Our study design hindered the identification of peo-
ple with limited treatment adherence, and whose 
experiences could have been informative.
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reasons for dropout.6 A particularly pertinent finding 
relates to the reported power imbalances between people 
who use drugs and professionals, where stigma, stereo-
types and discriminatory practices are embedded within 
the cultural context of a drug service.7
In the UK, in 2017–2018, 14.4%8 of those receiving 
OST obtained their prescription from GPs. In primary 
care, people in OST can also engage with other allied 
health professionals, such as key workers. Key workers are 
trained health and social care professionals who deliver 
psychosocial interventions and support people who use 
drugs making positive changes and work towards recovery. 
They also liaise with GPs to manage prescriptions, as well 
as collaborating in assessments and clinical reviews.
As specialist drug and alcohol treatment services have 
seen a decline in funding and move towards third sector 
provision,9 the role of primary care in the delivery of 
OST has never been more important. Primary care is 
the second most common provider of OST in the UK, 
either as the sole provider or in a shared care process with 
specialist services. Primary care provides an opportunity 
for people who use drugs to be treated like any other 
person and enables health conditions, including mental 
health needs, to be addressed alongside treatment for 
drug use.10 Primary care facilitates the identification of 
issues related to drug use in people seeking help for other 
physical and mental health issues11 and can ‘normalise’ 
drug treatment, with the potential to reduce the stigma 
of attending a specialist drug service.7
There are, however, challenges to managing drug 
use in primary care. Press et al12 interviewed people in 
OST in primary care in Baltimore (USA). They found 
that optimising the interpersonal relationship between 
people who use drugs and physicians is key in OST. Short 
appointments in primary care may not allow enough 
time for more complex cases or developing supportive 
rapport with people.12 There is also literature suggesting 
that people who use drugs ‘wished’ their GPs had greater 
knowledge about drugs and addiction, which in turn 
would enable them to foster less judgemental relation-
ships and treat people who use drugs as ‘people they care 
about’.12
The experiences of people in OST via UK- based 
primary care services have been little explored. Given 
that primary care is an important setting for the care of 
people who use drugs, it seems imperative to understand 
what we can learn from them in terms of how it feels to 
receive treatment in this setting. In doing so, there is 
scope to improve treatment experiences and optimise 
successful outcomes, as well as promoting the agency of 
those for whom the services are designed. Also, knowing 
what aspects of OST are valuable to people allows us to 
better adjust for any changes/restrictions affecting treat-
ment delivery (eg, financial crisis).
This study aimed to understand the experience of 
people in OST in primary care settings. More specifi-
cally, it sought to identify the aspects of care which were 
perceived by people who use drugs as most significant 
to their recovery journey, in their own words, including 
aspects which were either helpful or that made it difficult 
to be in treatment.
METHODS
Study design and setting
This was an exploratory qualitative study based on indi-
vidual, semistructured interviews with people who use 
drugs. These were recruited from primary care services in 
three UK urban areas (Leeds, London and Nottingham) 
and one charity (third sector provider) providing OST on 
a shared care basis (London).
Patient and public involvement
One person from the target population was invited to 
comment on the research proposal, the application form 
for the Ethics Committee and the interview schedules to 
ensure that the methodology and terms used were non- 
judgemental, meaningful and feasible in this context. 
During data analysis, another person in OST was invited 
to comment on the preliminary version of the thematic 
map to ensure our interpretations were aligned with the 
experience of this group in treatment.
Participants
Study participants were adults (over 18 years old) 
receiving OST in primary care, either with methadone 
or buprenorphine. Potential participants receiving other 
forms of treatment for licit substances (eg, alcohol and 
tobacco) or receiving OST via specialist services only were 
not included in the study.
Recruitment
To identify eligible participants, we worked with GPs 
and key workers delivering OST in primary care, invited 
through UK professional networks (eg, https:// smmgp. 
org. uk/). These professionals explained the study to 
people in OST at their practices. Those who met the 
inclusion criteria, expressed an interest and agreed for 
their contact details to be shared with the research team 
were invited to the study. Whenever possible, study partic-
ipants were purposively selected according to age, gender 
and length of time in treatment (ie, less than 6 months, 
6–12 months, 1–5 years, >5 years) to obtain a variety of 
experiences. Interviews were conducted between January 
and March 2019. All study participants were asked to read 
the information sheet and to provide written consent 
before the interview.
Data collection
Interviews were conducted by the first author (PCGA, PhD 
in Psychology, researcher in clinical psychology for 10 years), 
who was unknown to participants prior to the interview. 
The interview topic guide (online supplemental appendix 
1) was semistructured and based on the critical incidents 
technique.13 14 During the interview, study participants were 
encouraged to discuss their personal experience, in their 
own words, and to focus on issues raised by them, with limited 
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prompts from the researcher. Interviews were audio- recorded 
with study participants’ permission and transcribed verbatim 
by a professional transcription service. Before the interview, 
study participants were encouraged not to mention any 
names of professionals, services, locations or any other infor-
mation that could identify them. Any potentially identifiable 
information shared was removed from transcripts. At the end 
of the interview, study participants were asked to complete a 
basic sociodemographic form (eg, age group, employment 
status, educational background). All study participants were 
given a £20 voucher as recognition for their support. Inter-
views were conducted in a private room within the primary 
care service or charity, in which only the researcher and study 
participant were present to ensure confidentiality.
Data analysis
A thematic analysis approach15 was adopted using a 
‘bottom- up’ iterative process. Thematic analysis was 
chosen because it is a flexible, non- theoretical approach 
that aims to examine ‘the perspectives of different 
research participants, highlighting similarities and differ-
ences, and generating unanticipated insights’.16 Analysis 
was primarily conducted by the first author (PCGA) in 
collaboration with a multidisciplinary research team 
(FAS, medical sociologist; SM, GP registrar; NP, clinical 
psychologist; AW, consultant addiction psychiatrist; CF, 
GP with special interest in substance use).
The codes were first generated deductively, by inter-
preting data according to what was described as ‘helpful’ 
and ‘not helpful’ for people in OST; and then inductively, 
according to the underlying meaning of each text unit. 
Regular meetings were held between the first author and 
other team members to reduce the risk of bias in the 
analysis. The preliminary version of the thematic map 
was discussed with a study participant to seek feedback on 
whether the themes and subthemes reflected the experi-
ence of people in OST in primary care.
The first author recorded her thoughts in a researcher 
diary during data analysis to increase critical reflexivity 
and keep a log of all the decisions made around the 
coding and theme generation process (a summary of key 
steps is presented in online supplemental file 1). Data 
were analysed with the support of NVivo V.12.
RESULTS
Participant characteristics
Twenty- four people in OST were interviewed until 
data saturation was reached. The majority (n=20) were 
prescribed methadone. Most interviews (n=16) took 
place at the study participant’s general practice. Eight 
interviews were carried out at a charity. Interviews lasted 
an average of 28 (SD=8.6) min, ranging from 14 to 44. 
See table 1 for a summary of sample characteristics.
What is the experience of people receiving OST in primary 
care?
Ten major themes emerged from the 24 interviews with 
people in OST about their treatment experience. These 
themes represented aspects deemed as important for 
people who use drugs when engaging with GPs and key 
workers in one- to- one consultations; and when engaging 
with the primary care service in general, for example, 
experience of booking appointments, interactions within 
administrative staff or service accessibility issues. These 
themes are summarised in table 2 and are described in 
more detail.
Theme 1: ‘Being treated like a human being’ (humanised care)
During the interviews, study participants highlighted that 
‘being treated like a human being’ by GPs and key workers 
was crucial to their recovery journey, which was referred 
219 times across the study. This meant having the oppor-
tunity to discuss clinical decisions, instead of being forced 
to engage in a treatment plan unilaterally designed by 
GPs and/or key workers; being respected as a person 
and having treatment tailored to individual needs, as 
opposed to being provided with standardised informa-
tion and ‘one- size- fits- all’ plans. As Rob described during 
his interview, being treated as a human being while on 
methadone treatment means feeling ‘normal’ as opposed 
to an ‘addict’. Similarly, Josh described how helpful it 
feels coming to the service and “being treated like a person, 
I know I can come here… and staff are not going to get ‘sit over 
these’, or ‘get him out quick’. They hear what you are saying. 
I think that’s important”. For another study participant 
taking buprenorphine, William, being valued as a person 
implied that professionals “don’t push you in a direction and 
say, ‘This is what you should do.’ They look at what you need 
and what direction you want, and how you want to do it”.
Theme 2: ‘I know she is on my side’ (individual bond/
connection with the professional)
The individual bond/connection with GPs and key 
workers was reported as one of the most important 
aspects of treatment, which emerged 159 times during 
interviews. A good connection encompassed feeling 
Table 1 Study participants’ self- defined characteristics (N=24)
N
Gender Women: 10; men: 14
Ethnicity White British: 19; other white background: 3; Asian Indian: 1; Black Caribbean: 1
Employment status Full- time: 2; part- time: 1; unemployment: 21
Education No qualification: 10; GCSEs/A- levels: 10; higher education diploma: 3; postgraduate education: 1
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trusted, understood and professionals being approach-
able, caring, dependable, kind and willing to listen. Jane, 
for instance, was started on a prescription of methadone 
less than 6 months ago, and she values that her GP is 
“very understanding. I’ve had a few times when it’s been a bit 
wobbly. I’ve had a few stressful situations and I’ve had a couple 
of lapses as well, but I feel like I can be open. I don’t need to hide 
anything. He treats me like, ‘That’s fine’.” In line with this, 
not feeling cared for by professionals was also hinted as 
a potentially negative experience. Mark, for instance, 
explained that some key workers are “doing it because they 
need a job, because they’re in a situation where they can’t get 
anything else. So, they do it, but how much do they actually 
care about you? Do they really give a shit? That’s the truth. I 
think some people do; I think some people don’t.” Ricky raised a 
similar point in his interview, by saying how important it 
was that “they do care, I know that they’re not just there because 
they have to be there, they’re not just doing it because they’re 
Table 2 Thematic map representing the experience of people in OST in primary care
Overarching theme(s) Theme(s) Subtheme(s) Frequency




Person who uses drugs and 
the professional
‘Being treated like a human 
being’ (Humanised care)
Sharing decisions 8 36 219
Tailoring treatment to own needs 19 41
Power differences between people who use 
drugs and staff
2 6
Feeling judged 13 45
Not feeling pushed 9 32
Feeling respected 12 43
Feeling ‘normal’ vs an ‘addict’ 8 16
‘I know she’s on my side’ 
(Individual bond/connection with 
the professional)
Feeling trusted 3 4 159
Being approachable 10 29
Willing to listen/Not having a ‘proper chat’ 11 27
Being dependable 4 12
Caring about me 17 41
Feeling understood 10 15
Being kind 9 25
Leaning on professional 1 1
‘Putting too much’ on professional 2 5
‘He knows what he’s doing’
(Professionals’ experience and 
knowledge)
Having specific resources for people who 
use drugs
6 12 76
Having staff with lived experience of drug 
use
6 15
Having staff with knowledge of drug use 8 49
Person who uses drugs and 
the general practice
‘You need it under one roof’ 
(Holistic care)
Going beyond drug use 18 52 74
Liaising with other services 7 15
Having mental health resources 3 7
‘Feels like family’ (Familiarity) Knowing who I am 21 95 95
‘They’ve bent over backwards 
to help me’ (Professionals’ 
commitment and availability to 
help)
Having help when in need 15 53 82
Having time to talk 7 13
Easiness to book appointments 5 16
‘I don’t have to meet any 
other people who use drugs’ 
(Anonymity)
Feeling anonymous 6 16 53
Distance from other people who use drugs 9 28
Moving on 1 9
‘Being close to my house’ 
(Location)
Convenience of location 8 13 13
‘They keep in constant contact’ 
(Collaborative teamwork)
Information sharing within clinical team 8 16 16
‘The prescription is so tied 
down’ (Flexibility and changes 
around the treatment plan)
Changes within the service 1 1 96
Being flexible 14 55
Prescribing routine 12 40
OST, opioid substitution treatment.
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getting paid, if you get what I mean. He genuinely helps me 
out.”
Theme 3: ‘He knows what he’s doing’ (professionals’ 
experience and knowledge)
Study participants valued when GPs and key workers in 
primary care had knowledge of drug use and awareness 
of resources for people who use drugs, which emerged 
76 times in this study. For instance, Claire, who has been 
prescribed methadone for the past 2 months, said that 
the GP “made [her] feel reassured because he was obviously 
very capable. He’d obviously been doing this for years”. Michael 
expressed similar views to Claire’s in his interview: “Some 
have been so long, or they’ve been working for addiction for so 
long, or whatever, and they know everything. They know the 
behaviour, they know the lies that they say when they’re trying, 
sometimes, manipulating, to get what they want. You know, they 
know all these things.” Some study participants also valued 
staff with lived experience of drug use. One such person 
was Joe, who had been on buprenorphine for 7 years in 
the same service. Joe highlighted that if “they’ve never been 
on drugs so, they’ll never understand. (…). If they knew that, 
the pain that I’ve gone through this week”, they would prescribe 
“something to help me sleep at night”.
Theme 4: ‘You need it under one roof’ (holistic care)
Another aspect highlighted by study participants as signif-
icant to their recovery journey was having further mental 
and physical healthcare, which emerged 74 during the 
interviews. This was described as going beyond drug use 
in their treatment plans, and the opportunity to liaise with 
other health and social care services and charities. For 
Mary, who is prescribed buprenorphine, this is important 
because drug use “causes a lot of medical problems. So, you 
always have backfires in one or the other, so it makes it really 
helpful that you can come to deal with both issues at the same 
time. So that you can come and get both sorted.” An emphasis 
was put on mental health resources, which study partic-
ipants such as Laura believed to be key for recovery: “I 
think if they’re doing shared care, they should allow shared care 
to have a little bit of mental health or something like that here 
as well, maybe. So, it’s not all on my doctor”. Finally, some 
participants also valued having support beyond health 
issues. As James put it: “I got help with housing. I’ve had help 
with my benefit claim and my methadone, general health. Quite 
a spectrum really. I mean, I had a benefit claim not long back 
and I had to get my doctor write me a letter for all them, and 
that doesn’t seem to be any trouble. And he doesn’t charge you 
for those. Usually a doctor will charge you a tenner for them, but 
they don’t here”.
Theme 5: ‘Feels like family’ (familiarity)
Study participants valued the experience of ‘feeling like 
family’ at the primary care service, which was discussed 
95 times during the interviews. In our study, this meant 
having GPs, recovery workers and administrative staff 
who have known study participants for long periods 
of time, and who are familiar with their personal life 
circumstances and how they have changed over time. As 
an example, Neil reported that prior to being prescribed 
with buprenorphine, his GP had “known me as a person since 
I was like 20 years old, but I’ve always been having problems with 
drugs, so she’s always known me as that kind of person”. Robert 
shared a similar experience, when he said that “they all got 
that same kind of environment, that same kind of attitude. It’s 
like one big family here and when you come you all get treated 
like that. So, it’s very welcoming.” Consequently, the opposite 
situation—lack of familiarity—was reported as a negative 
experience. For instance, in his interview, Ricky shared 
how he disliked not being recognised by his GP: “I’ve seen 
the woman like five times and when I went last month she said, 
‘Have I seen you before?’ Like she doesn’t even know me.”
Theme 6: ‘They’ve bent over backwards to help me’ 
(professionals’ commitment and availability to help)
Study participants valued when they felt that GPs, key 
workers and administrative staff went over and beyond 
their expected roles or duties to support them, including 
being available whenever needed. This theme was 
discussed 177 times during the interviews. For instance, 
this meant being told by professionals to contact the 
service at any time, either in person or via telephone, or 
facilitating the process of booking appointments. This 
was particularly meaningful for people starting their treat-
ment, such as Michelle, who valued when “the doctor said to 
me that if I just turned up here and I didn’t have an appointment 
he’d always see me. That’s quite nice to know that I’ve got that 
support.” In line with theme 5, the level of commitment 
from professionals was also highlighted when support 
was needed beyond drug use issues, as Claire put it: “I’ve 
always found that they’ve always tried to go above and beyond 
what I expected would be possible. They’ve turned around and 
said, something like when I say, even before I knew that a problem 
was going on with the paralysis, I was just stuck in a bed and 
I couldn’t go to the toilet and I was having trouble and they 
came out and the doctor was able to bring me some NHS provided 
nappies.” Having time to talk in consultations was also 
highlighted by study participants as a key aspect in their 
recovery journey. As a person receiving buprenorphine 
for more than 5 years, Martin explained that if “you’re still 
in the situation where you’re seeing your keyworker and they’ve 
got someone else coming in 20 minutes’ time. You can’t really go 
into too much. ‘Why are you stressed? Why can’t you sleep?’ It’s 
not as simple as that.”
Theme 7: ‘I don’t have to meet any other people who use 
drugs’ (anonymity)
Receiving treatment in primary care alongside the general 
population was another aspect valued by people in OST, 
which was mentioned 53 times during interviews. In other 
words, people in OST appreciated feeling anonymous, 
which meant attending for generalised health concerns, 
and where other people were not aware of their drug use 
issues. From this point of view, study participants consid-
ered that going to primary care for their OST made them 
feel like moving on to a different stage in their recovery 
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journey. For instance, John has been prescribed OST for 
over 5 years and the anonymity of being at a GP surgery 
made him feel “confidence, nobody knows about you, why you 
are in there. Just surgery practice and everybody’s doing their 
business and that’s it. It’s fine.” A similar experience was 
reported by Connor, who has been receiving buprenor-
phine for over 1 year in primary care. In Connor’s words, 
“I’m a druggie, don’t get me wrong, but I’m a recovering druggie, 
and I don’t like to be reminded of that. I don’t like to sit with 
people that are just squiffy, that are- You can see they’re on drugs, 
and they're sat there rubbing their noses and blooming drinking.” 
Mark’s experience at primary care was similar: “(at the 
GP), I’m not sat with a load of other—This sounds really contra-
dictory and condescending for myself, but I’m not sat with all the 
druggies that are still active.”
Theme 8: ‘Being close to home’ (location)
Being engaged with a service that is geographically 
close to home was mentioned 13 times as an aspect that 
impacts the recovery journey during OST, due to its ease 
and convenience. For instance, Gary has been receiving 
treatment with methadone for over 5 years at his local GP 
surgery, and according to him, he likes ‘this place because 
I’ve been living just around here, it’s not that far from me you 
see’.
Theme 9: ‘They keep in contact all the time’ (collaborative 
teamwork)
Study participants valued when different GPs, key workers 
and other health professionals worked collaboratively in 
their treatment plan, which emerged 16 times during the 
interviews. This referred to when professionals shared 
information about their clinical situation. Rebecca has 
been taking methadone for 10 years and finds that it 
“works well, yes. I think it’s quite important, because at the end 
of the day, I suppose, they are only workers. So, they can fall 
back on the doctor just as I can. So, yes, I actually do think 
it’s a good thing”. From this perspective, study participants 
believed that lack of communication between profes-
sionals can lead to negative outcomes. Michael, who has 
been receiving buprenorphine for 3 years, for instance, 
discussed how ‘horrendous’ it was when his prescription 
was “stopped because they changed my worker and that worker 
didn’t know my situation and they stopped my script.” Maria 
shared a similar experience and how that affected her 
consultation schedule: “If they shared the information, which 
obviously should be in a file, they’d know I was never going to be 
there for six o’clock because I’ve been working for years. My shift 
hasn’t changed in that sense.”
Theme 10: ‘The prescription is so tied down’ (flexibility and 
changes around the treatment plan)
Finally, the flexibility of the service and the treatment plan 
was also highlighted by study participants as important to 
recovery, which was mentioned 96 times during the inter-
views. This referred to situations in which the clinical 
and administrative staff adjusted for any changes in the 
treatment plan, as well as the impact of changes within 
the service in general. For instance, Julie has been on 
buprenorphine for 3 years and feels that it is very helpful 
when there is flexibility around the prescriptions, so that 
“if you have messed up or you have made a mistake, you can still 
ring them the next day or come in the next day and they will try 
and find somebody to see you and give you a help.” Another 
study participant on buprenorphine, Paul, shared how 
changes within service staff impacted him during treat-
ment: “I could have relapsed [because of the error in the 
prescription]. I could have ended up back on drugs after years 
and years – buying my house, buying a nice car, working my 
way up at where I’m at and getting myself back on track. From 
someone that didn’t know what they were doing, just coming 
in and pulling a script, thinking they were clever, that could 
have put me back to scratch, back to day one”. Participants 
also expressed frustration about the impact of missing 
appointments on their care plans. As Robert put it: “That 
side is more of a frustration, because they’ll send me letters saying, 
‘You didn’t turn up to this appointment, you were ten minutes 
late to this one, we’re going to stop your script if you don’t…’ I’ve 
been working for years”.
DISCUSSION
This study sought to understand the experiences of 
people receiving OST via GPs and key workers in primary 
care services. In the next sections, we will discuss the 
key lessons learnt from study participants and reflect 
on how these lessons can help us improve the quality of 
care provided to this population, from a primary care 
perspective.
People in OST want to be treated like any other person and 
value continuous, compassionate and holistic care, which can 
be provided by primary care professionals
In the UK, drug use treatment has been successfully deliv-
ered in primary care settings for over 30 years, as part 
of an effort to normalise treatment delivery and bring it 
in line with other chronic conditions.17 This is illustrated 
by the growing number of people engaged in OST in 
primary care, and the increasing training opportunities 
and guidelines for primary care professionals managing 
substance use (eg, RCGP Certificate in the Management 
of Drug Misuse Parts 1 and 2).17 In our study, it was 
encouraging to learn that people perspectives are aligned 
with that of professionals and researchers, that is, that 
primary care provides a valuable setting to deliver treat-
ment to people with problems related to drug use.
Primary care services are designed to accommodate a 
whole variety of concerns from ‘cradle to grave and every-
thing in between’.17 On the other hand, drug use is asso-
ciated with various health conditions across the lifespan, 
from adolescence to older adulthood.18 Hence, primary 
care can play an important role in caring for the person 
and their comorbidities and not only his/her drug use 
issues. This role seems to be acknowledged by our study 
participants, with the experience of having care at primary 
care deemed as important for their recovery journey.
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Privacy concerns and how primary care supports people 
in keeping their anonymity as people who use drugs was 
another aspect appreciated by study participants. This has 
been addressed in the literature, in which people refer 
to being in methadone treatment as a ‘dirty secret’ that 
needs to be protected, so they can ‘pass as normal’ (p. 
263).19 Previous studies have also suggested that people 
fear having drug use in their clinical records and how that 
may negatively impair their general healthcare.20 While 
clinic record confidentiality is a basic right for all those 
receiving healthcare in the UK’s National Health Service, 
these comments highlight the stigma many people feel. In 
other words, whenever possible, non- specialist treatment 
may be preferable due to its role in mitigating stigma.
Another aspect which people who use drugs seem to 
value when in treatment is continuity of care. Research 
indicates that long- term trusting relationships between 
people and GPs decrease overall mortality, cardiovas-
cular events and healthcare costs.21 Continuity of care 
has also been associated with better treatment outcomes 
and quality of life in chronic conditions.22 For instance, in 
other chronic conditions such as diabetes, people report 
that primary care professionals are vital in coordinating 
and facilitating access to specialist care when needed.23 
This means that when drug use treatment is addressed 
in primary care, people not only experience continuity 
of care; but are also more likely to better engage with 
specialist services, for example, inpatient units for detoxi-
fication, bringing down barriers such as fear of treatment 
or admission difficulties.24 This is crucial when caring 
for comorbid conditions among an ageing population, 
allowing GPs to see people, instead of single conditions 
in isolation, which is particularly important for those with 
mental health/pain issues.25
Considering this, our paper not only reinforces that 
managing drug use fits within the generalist approach of 
primary care services; but also, that people who use drugs 
value the opportunity of having primary care profes-
sionals involved in their recovery journey. Therefore, 
these findings point towards a continued involvement of 
primary care in the delivery of drug use treatment, and 
that this is accounted for in local, regional and national 
healthcare budgets.
Further training about drug use and OST could be provided to 
primary care professionals
Study participants found it helpful when they perceived 
professionals as experienced and with expert knowledge 
about drug use. Even though primary care is the second 
most common provider of OST in the UK,8 research 
shows that professionals in general practices may be reluc-
tant, less prepared and motivated to manage drug use in 
comparison with other health conditions.26 27 It has also 
been suggested that primary care professionals may find 
it difficult to enquire about drug use in their consulta-
tions, and that they may experience a lack in confidence, 
knowledge and skills when dealing with stigma around 
drug use and managing the complex needs of people 
who use drugs.20 Despite the existing career and profes-
sional development opportunities in the management 
of drug use in primary care, it would be advantageous to 
strengthen the curricula of health professionals, medical 
students and GPs in how to engage with this group. 
This is particularly relevant for professionals working in 
geographical areas where drug use is prevalent, and where 
people who use drugs are likely to seek medical care for 
various physical and mental health concerns. Increasing 
training to GPs is also paramount in a current scenario 
where prescription rates of long- acting and short- acting 
opioids for pain management are escalating in the UK.28
In addition to having expert knowledge, people who 
use drugs valued key workers with lived experience of 
drug use. There is limited evidence on the effectiveness 
of interventions delivered by staff with lived experienced. 
However, findings drawing from peer- led interventions 
are promising, as they indicate that involving staff with 
lived experience is potentially associated with a reduction 
in the use of tobacco, alcohol and cannabis.29 The involve-
ment of peers in treatment as a positive experience is not 
surprising. Professionals with lived experience of drug 
use not only share an affiliation with people in treatment, 
but also have a sense of deep understanding about their 
situation.30 The involvement of staff with lived experi-
ence can be rooted in theoretical concepts such as the 
social dynamic theory, which stipulates that people will 
most likely relate to and assimilate information as cred-
ible if provided by someone with whom they identify31; 
or the social norms theory, which indicates that people 
with lived experience are better placed to help people 
modifying their misperceptions about social behaviours 
and perceptions.32
A good relationship with primary care professionals is key to 
the recovery journey
Having a good connection with professionals is key to 
any healthcare encounter, and interventions targeting 
drug use are not an exception, as our study shows. Non- 
specific treatment factors, such as the therapeutic rela-
tionship, are believed to explain between 30% and 70% 
of therapy outcome variance.33 Research has shown that a 
good therapeutic relationship is likely to improve psycho-
logical well- being and general distress,34 treatment reten-
tion35 and confidence that the treatment will produce 
improvements.36 Specifically, it has been suggested that 
a weak therapeutic relationship in drug treatment may 
contribute to early treatment dropout and a higher level 
of distress during treatment.37 38
The importance of the therapeutic relationship is 
acknowledged in the guidance produced by the Royal 
College of General Practitioners for the Management 
of Substance Use.39 Considered by RCGP as a ‘powerful 
tool’, the therapeutic relationship is however ‘inconsis-
tent, unmeasurable and poorly defined’ (p. 308). Conse-
quently, further research is needed to explore the main 
components of successful therapeutic relationships in 
OST and how we can best support professionals and 
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people who use drugs to establish these in clinical prac-
tice. From a clinical practice point of view, our study 
suggests that interpersonal and empathetic attitudes, 
such as showing kindness, being willing to listen or 
demonstrating support, should not be underestimated 
and can boost the attitudes of people who use drugs 
towards treatment.40
A more humanised and destigmatised environment 
contributes to better treatment experience
The literature suggests that non- judgemental attitudes are 
fundamental to engage people with complex biopsycho-
social issues.41 According to social psychology theories, 
degrading and discriminatory behaviours within clinical 
settings, and towards stigmatised groups, are related 
to unconscious attributions of a lower human status to 
people, designated as dehumanisation.42 In medical 
contexts, dehumanisation is related to staff avoidance 
responses, hindering helping behaviours and demental-
isation, in which the ingroup (ie, professionals) tends to 
deny the outgroup (ie, people seeking treatment) the 
capacity of feeling emotions and goal- planning.42 People 
who feel dehumanised are likely to experience cognitive 
deconstructive states, sadness and anger,43 which can 
negatively affect their experience in treatment, which is 
illustrated in our study findings.
The discourse of study participants also pointed to the 
negative consequences of stigma and self- stigma (I’m a 
druggie, don’t get me wrong) in the recovery journey. This 
is well documented in the literature, which associates 
stigma with social identity threat (ie, devaluation based on 
group membership), higher stress levels and an increased 
vigilance for signs of mistreatment, leading to situations 
being interpreted as discriminatory even when they are 
not.44 Experiences of stigma may hinder help- seeking and 
have a negative impact on other components of recovery, 
such as employment or reintegration; and reinforce nega-
tive feelings of self- worth, self- esteem and blame.45
The literature suggests that stigma undermines confi-
dence and self- efficacy, which can be counterproductive 
to treatment.46 As highlighted earlier, being hypervigilant 
due to experienced stigma may interfere with the devel-
opment of a trustful relationship with professionals, which 
is likely to negatively affect treatment.47 Further qualita-
tive research is needed to shed light on the processes of 
stigma and self- stigma in people who use drugs and the 
role of primary care services in dealing with such experi-
ences of stigma.
Recovery journeys in OST should be flexible, tailor-made and 
collaboratively designed with people
Overlooking the uniqueness of a person is another form 
of dehumanisation in healthcare, as well as denying his/
her personal agency and self- efficacy.42 44 Our study aligns 
with these ideas, illustrating how people who use drugs 
appreciate taking part in clinical decision- making and 
expressing their thoughts about their recovery journey. A 
recent review pointed to evidence showing that matching 
treatment to people preferences contributes to a reduc-
tion in drug use.48 This aligns with the ‘expert patient’ 
approach suggested by Tattersall,49 which states that 
people can ‘contribute their skills and insights for the 
further improvement of services’ (p. 227), and that this 
involvement could help reduce the severity of symptoms 
and improve confidence, resourcefulness and self- efficacy, 
which tends to be low in this population. When people 
feel part of the team, they are also likely to ‘care’ for the 
professional in return, which is illustrated by worries such 
as ‘putting too much on the professional’. Even though it is 
debatable whether it is the person’s responsibility to care 
for professionals’ well- being, this suggests that a successful 
therapeutic bond is likely to promote a good and mutu-
ally beneficial patient–professional collaboration.
Finally, flexibility was another issue discussed by study 
participants. Further evidence is needed to explore 
the impact for staff of being ‘immediately available’ for 
people who use drugs, in terms of workload and keeping 
up professional boundaries. The literature has reported 
that professionals delivering treatment for drug use are 
at high risk of burn- out, impacting on their well- being 
and relationships with people.50 However, in this popu-
lation, there could be consequences to people of limited 
staff availability and flexibility, particularly when it comes 
to issues around medication prescription (‘I could have 
relapsed’). For this reason, it is important that training 
organised locally is provided to professionals who are 
likely to engage with this group. This would ensure that 
professionals have knowledge and experience on how to 
overcome potential challenges of providing OST, as well 
as the level of support needed by people who use drugs 
within the remit of each GP practice and the implications 
of that.
Limitations of the study
This study is not without limitations. The first of them 
is the sample size which, even though appropriate for a 
qualitative study, hinders the generalisability of the find-
ings. A more diverse sample could have been collected, 
given that there are geographical variations in terms of 
services provided and availability of staff. For instance, 
we included GP practices from different locations, but 
all participating research sites were located in urban 
contexts, which means that the experiences of partici-
pants may not be representative of service users from for 
example, non- urban GP practices.
Another limitation is that our sample was recruited 
conveniently through our research team networks 
and participants were invited through their GPs, due 
to the research team being unable to identify eligible 
participants and reach out without their consent. This 
recruitment strategy facilitated the process of accessing 
participants, but we are aware of potential GP biases when 
inviting their patients to the study.
Finally, our recruitment process and how we obtained 
our sample may have limited our access to patients with 
negative experiences of treatment and those who are 
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less like to adhere to treatment. In the future, it would 
be important to extend recruitment to harm reduction 
services, such as supervised injection facilities, to maxi-
mise the likelihood of engaging with individuals who may 
have fewer positive experiences and limited motivation to 
engage with treatment.
CONCLUSION
As we face a rise in mortality associated with drug use, 
and poor treatment retention rates, understanding what 
people who use drugs appreciate in treatment is para-
mount. This is particularly important in the context of 
primary care services, which can be the first point of 
contact with the healthcare system for many of people 
seeking treatment.
This study aimed to provide first- hand accounts of how 
it feels for people to be in OST in primary care services. 
Overall, our findings point to primary care being a setting 
that helps people with opioid addiction in their recovery 
journey. People’s accounts have pointed to what works 
and does not work from their perspective. This knowl-
edge may support primary care professionals managing 
drug use by raising awareness of how people experience 
treatment. This study has also suggested that non- specific 
therapeutic factors, such as empathy, kindness, showing 
support, willingness to listen or even convenience of loca-
tion can be powerful tools to facilitate treatment engage-
ment within this group.
In summary, further engagement with people who 
use drugs will help providers developing an inclusive 
approach to primary care in the delivery of drug services. 
This will allow people from stigmatised populations and 
with complex health needs to receive the highest stan-
dards of care, in line with the Word Health Organisation’s 
Alma Ata declaration goal of ‘health for all’.
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